Pig Kidney Keeps Patient Off Dialysis for Nine Months in eGenesis Breakthrough
Genetically engineered pig kidneys sustained kidney function for over eight months in multiple patients, with one case published in The Lancet.
Summary
eGenesis has reported that five patients with end-stage kidney disease received genetically modified pig kidneys through an FDA compassionate-use program. Three maintained kidney function for over eight months without dialysis. One patient — Tim Andrews — went nine months dialysis-free before successfully receiving a human donor kidney, a world record for xenotransplantation. Two patients have now transitioned from pig to human kidneys, proving the pig organ can serve as a genuine bridge therapy. The kidney, called EGEN-2784, was engineered with three types of genetic edits: removing pig sugar antigens that trigger immune rejection, inserting seven human immune-regulating genes, and silencing pig retroviruses. The FDA has cleared a formal Phase 1/2/3 trial called RESTORE, enrolling 33 patients aged 50–70 starting in early 2027.
Detailed Summary
End-stage kidney disease affects over 800,000 Americans, yet only 28,000 transplants were performed in 2024. Dialysis, the primary alternative, carries a five-year mortality rate of 60% — worse than many cancers. This dire gap has accelerated interest in xenotransplantation, using genetically engineered pig organs to bridge the supply shortage. eGenesis, a Cambridge-based biotech, has now published results that move the field from curiosity to credible clinical option.
Five patients received eGenesis' EGEN-2784 pig kidney under FDA expanded access since March 2024. Three maintained sustained kidney function for more than eight months without dialysis. One patient, Tim Andrews, achieved nine months of dialysis independence — a global record — before receiving a human donor kidney 82 days after the pig organ was removed. His case appeared this week in The Lancet.
The engineering behind EGEN-2784 is extensive and targeted. Three glycan antigens — sugar molecules that trigger violent immune rejection — were deleted from the pig genome. Seven human genes were inserted to modulate immune response, reduce inflammation, and improve vascular compatibility. Endogenous pig retroviruses were also silenced, addressing a long-standing biosafety concern about cross-species pathogen transmission.
Perhaps the most clinically significant finding is that two patients successfully transitioned from pig to human kidneys — the first documented cases of xenotransplant-to-human-transplant bridging. This reframes pig kidneys not as a last resort but as a genuine waitlist management tool, preserving life and organ eligibility simultaneously.
The FDA has cleared a formal Phase 1/2/3 trial, RESTORE, targeting 33 patients aged 50–70 on the human donor waitlist, expected to begin Q1 2027. Caveats remain: the expanded access cohort is tiny, follow-up is short, and long-term immunosuppression burden is uncharacterized. Still, for a patient population facing 60% five-year mortality on dialysis, this represents a meaningful and rapidly maturing therapeutic option.
Key Findings
- One patient achieved nine months dialysis-free with a pig kidney before successfully receiving a human transplant — a world record.
- Three of five patients sustained kidney function over eight months without dialysis using EGEN-2784 pig kidneys.
- Two patients transitioned from pig kidney to human donor kidney, proving xenotransplants can serve as bridge therapy.
- EGEN-2784 uses three types of genetic edits: antigen deletion, human gene insertion, and retrovirus silencing to reduce rejection.
- FDA cleared a Phase 1/2/3 trial (RESTORE) in 33 patients aged 50–70, starting Q1 2027.
Methodology
This is a news report summarizing expanded access (compassionate use) clinical data from eGenesis, with one patient case published in The Lancet. The evidence basis is a small five-patient cohort outside a formal randomized trial, limiting statistical conclusions. Source credibility is high given Lancet publication and FDA Phase 1/2/3 clearance.
Study Limitations
Only five patients were treated under expanded access; the cohort is too small for statistical confidence in efficacy or safety. Long-term immunosuppression requirements, infection risk, and organ durability beyond nine months remain uncharacterized. Primary source data beyond the single Lancet case report should be reviewed when the full dataset is published.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: